NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc. (NASDAQ:CLVS) between May 20, 2014 and November 13, 2015.
You are hereby notified that Levi & Korsinsky has commenced a securities class action lawsuit in the USDC for the District of Colorado. If you purchased or otherwise acquired Clovis Oncology securities between May 20, 2014 and November 13, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/clovis-oncology-clvs
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; and (5) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA.
If you suffered a loss in Clovis Oncology you have until January 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Robinhood Expands Sports Event Contracts With Player Performance Wagers
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 



